阿替普酶联合华法林治疗慢阻肺合并肺栓塞的有效性分析(1)
摘要：目的 分析阿替普酶聯合华法林治疗慢阻肺(COPD)合并肺栓塞的有效性。方法 回顾分析2017年10月～2018年10月在我院诊治的90例慢阻肺合并肺栓塞患者临床资料，将其随机分为对照组和观察组，各45例，对照组采用肝素联合华法林治疗，观察组采用阿替普酶联合华法林治疗，对比两组临床治疗有效率、凝血功能指标(PT、APTT、TT、Fbg)、动脉血PO2、PCO2、血清心肌肌钙蛋白Ⅰ( cTnⅠ)以及不良反应。结果 观察组治疗总有效率(95.55%)与对照组(91.11%)对比，差异有统计学意义(P<0.05);治疗后两组患者PT、APTT、TT 较治疗前降低，Fbg升高，组间比较差异有统计学意义(P<0.05);治疗后两组动脉血PO2升高，动脉血PCO2、cTnⅠ降低，与治疗前对比，组间对比差异有统计学意义(P<0.05);两组均未发生明显不良反应。结论 阿替普酶联合华法林治疗COPD合并肺栓塞具有良好的有效性，且用药安全，同时在改善心肌损伤方面具有良好的效果。
关键词：阿替普酶;华法林;慢阻肺;肺栓塞
, http://www.100md.com
中图分类号：R563.3 文献标识码：A DOI：10.3969/j.issn.1006-1959.2019.05.046
文章编号：1006-1959(2019)05-0146-02
Abstract：Objective To analyze the efficacy of alteplase combined with warfarin in the treatment of chronic obstructive pulmonary disease with pulmonary embolism. Methods The clinical data of 90 patients with chronic obstructive pulmonary disease complicated with pulmonary embolism diagnosed and treated in our hospital from October 2017 to October 2018 were retrospectively analyzed. They were randomly divided into two groups： control group (n=45) and group (n=45). The control group was treated with heparin combined with warfarin. The patients in the observation group were treated with ateptidase combined with warfarin. The effective rate， coagulation function index (PT，APTT，TT，Fbg)，Arterial blood PO2，PCO2， serum cardiac troponin I (cTnI) and adverse reactions. Results The total effective rate of treatment in the observation group was 95.55% compared with 91.11% in the control group，the difference was statistically significant (P<0.05). After treatment， the PT， APTT and TT of the two groups were lower than before treatment and the Fbg was increased，the difference between the groups， the difference was statistically significant (P<0.05); after treatment， the arterial blood PO2 increased， arterial blood PCO2， cTnI decreased， compared with the pre-treatment， the difference between the groups was statistically significant (P<0.05); no significant adverse reactions occurred in either group. Conclusion Alteplase combined with warfarin is effective in the treatment of COPD with pulmonary embolism and is safe to use. At the same time， it has a good effect in improving myocardial damage.
Key words：Alteplase;Warfarin;Chronic obstructive pulmonary disease;Pulmonary embolism, 百拇医药(周笳 董丽霞)
关键词：阿替普酶;华法林;慢阻肺;肺栓塞
, http://www.100md.com
中图分类号：R563.3 文献标识码：A DOI：10.3969/j.issn.1006-1959.2019.05.046
文章编号：1006-1959(2019)05-0146-02
Abstract：Objective To analyze the efficacy of alteplase combined with warfarin in the treatment of chronic obstructive pulmonary disease with pulmonary embolism. Methods The clinical data of 90 patients with chronic obstructive pulmonary disease complicated with pulmonary embolism diagnosed and treated in our hospital from October 2017 to October 2018 were retrospectively analyzed. They were randomly divided into two groups： control group (n=45) and group (n=45). The control group was treated with heparin combined with warfarin. The patients in the observation group were treated with ateptidase combined with warfarin. The effective rate， coagulation function index (PT，APTT，TT，Fbg)，Arterial blood PO2，PCO2， serum cardiac troponin I (cTnI) and adverse reactions. Results The total effective rate of treatment in the observation group was 95.55% compared with 91.11% in the control group，the difference was statistically significant (P<0.05). After treatment， the PT， APTT and TT of the two groups were lower than before treatment and the Fbg was increased，the difference between the groups， the difference was statistically significant (P<0.05); after treatment， the arterial blood PO2 increased， arterial blood PCO2， cTnI decreased， compared with the pre-treatment， the difference between the groups was statistically significant (P<0.05); no significant adverse reactions occurred in either group. Conclusion Alteplase combined with warfarin is effective in the treatment of COPD with pulmonary embolism and is safe to use. At the same time， it has a good effect in improving myocardial damage.
Key words：Alteplase;Warfarin;Chronic obstructive pulmonary disease;Pulmonary embolism, 百拇医药(周笳 董丽霞)